Investors with a lot of money to spend have taken a bearish stance on Humana HUM.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HUM, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 54 uncommon options trades for Humana.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.
Out of all of the special options we uncovered, 38 are puts, for a total amount of $4,018,250, and 16 are calls, for a total amount of $699,769.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $290.0 for Humana over the last 3 months.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $200.0 to $290.0 over the preceding 30 days.
Humana Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
HUM | PUT | TRADE | BULLISH | 01/17/25 | $3.4 | $3.1 | $3.19 | $220.00 | $647.5K | 1.1K | 2.0K |
HUM | PUT | TRADE | BEARISH | 12/20/24 | $2.5 | $1.45 | $2.6 | $245.00 | $527.8K | 2.1K | 2.1K |
HUM | PUT | TRADE | NEUTRAL | 12/20/24 | $21.8 | $19.0 | $20.4 | $260.00 | $306.0K | 1.4K | 799 |
HUM | PUT | TRADE | BULLISH | 12/20/24 | $22.3 | $20.8 | $20.4 | $260.00 | $255.0K | 1.4K | 926 |
HUM | PUT | TRADE | BULLISH | 12/20/24 | $22.2 | $20.2 | $21.0 | $260.00 | $210.0K | 1.4K | 1.0K |
About Humana
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Following our analysis of the options activities associated with Humana, we pivot to a closer look at the company's own performance.
Present Market Standing of Humana
- With a trading volume of 2,664,992, the price of HUM is down by -8.58%, reaching $238.12.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 37 days from now.
Professional Analyst Ratings for Humana
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $301.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Humana with a target price of $301.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Humana options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.